Mydimed

Company Overview

Snapshot

Founded in September 2016 by Yuval Eyal, Mydimed operated with 1–10 employees. The company secured funding across one round from one investor, Samurai Incubate Israel, before ceasing operations in October 2021.

Business overview

Mydimed develops algorithms and software tools designed to predict and prevent adverse drug reactions (ADR) in high-risk, poly-pharmacy patients. The company leverages artificial intelligence and proprietary algorithms to derive insights from medical records, aiming to reduce morbidity and mortality. Its technology, based on medical research and advanced data science, analyzes electronic medical records to optimize the prediction of high-risk ADRs that could lead to hospitalization or readmission. Mydimed operates in the Health Tech & Life Sciences sector, specifically within Digital Healthcare and Medical Decision Support, serving healthcare providers, pharmaceutical companies, and seniors globally.

Company Intelligence Q&A

What is Mydimed's primary focus?

Mydimed focuses on developing algorithms and software tools to predict and prevent adverse drug reactions (ADR) among high-risk, poly-pharmacy patients.

When was Mydimed founded?

Mydimed was founded in September 2016.

Who is the founder of Mydimed?

Yuval Eyal is the Co-founder & CEO of Mydimed.

What technology does Mydimed utilize?

Mydimed utilizes artificial intelligence and proprietary algorithms to analyze medical records and predict adverse drug reactions.

When did Mydimed cease operations?

Mydimed ceased to operate in October 2021.